On 8 October 2024, MSD’s Keytruda® (pembrolizumab) and Astellas/Pfizer’s Padcev® (enfortumab vedotin) were approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a first-line combination treatment for unresectable or metastatic urothelial carcinoma (UC) in adults who are eligible for platinum-containing chemotherapy.
This follows approval of this combination therapy for the same indication in Europe on 3 September 2024. Enfortumab vedotin, an antibody drug conjugate, is being co-developed by Astellas and Pfizer under a global development and commercialisation collaboration.